Eph2A Inhibitors
1 drugsAbout Eph2A
Eph receptor A2 (Eph2A) is a receptor tyrosine kinase involved in cell communication, influencing cell migration, adhesion, and differentiation. Activated by ephrin ligands, it triggers downstream signaling cascades that regulate fundamental cellular processes.
Currently, there is no genetic evidence directly linking Eph2A to specific diseases, limiting confidence in target validation. However, its role in key cellular processes makes it a potential target for drug development.
Eph2A is targeted by one FDA-approved drug, STIVARGA (Bayer), a small molecule with three indications. This single drug highlights the potential, yet limited, therapeutic focus on this receptor.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Carcinoma, Hepatocellular with only 3 trials.
Top Drugs
Bayer is the only company with an approved drug targeting Eph2A.
The market is not competitive, but high barrier to entry due to limited clinical validation.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Eph2A, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing therapies and potentially improve efficacy.
Clinical Trials 293 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 77 | 52 | 10 | 14 | 84% |
| Phase 2 | 139 | 55 | 22 | 61 | 71% |
| Phase 3 | 66 | 46 | 8 | 12 | 85% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
5 Phase 3 trials testing approved Eph2A drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Eph2A. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2012 - 2012)
The first and only drug, STIVARGA, was approved in 2012.
The approval timeline indicates a potentially saturated market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 217 clinical trials targeting Eph2A.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities